Premium
Clinical significance and prognostic value of chromatin assembly factor‐1 overexpression in human solid tumours
Author(s) -
Polo Sophie E,
Theocharis Stamatios E,
Grandin Laure,
Gambotti Laetitia,
Antoni Guillemette,
Savigi Alexia,
Asselain Bernard,
Patsouris Efstratios,
Almouzni Geneviève
Publication year - 2010
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2010.03681.x
Subject(s) - proliferation marker , pathology , clinical significance , ki 67 , cervical cancer , endometrial cancer , biology , cancer , immunohistochemistry , cancer research , medicine
Polo S E, Theocharis S E, Grandin L, Gambotti L, Antoni G, Savignoni A, Asselain B, Patsouris E & Almouzni G
(2010) Histopathology 57 , 716–724
Clinical significance and prognostic value of chromatin assembly factor‐1 overexpression in human solid tumours Aims: Chromatin assembly factor‐1 (CAF‐1), whose function is critical for maintaining chromatin stability during DNA replication and repair, has been identified as a proliferation marker in breast cancer. The aim was to investigate CAF‐1 as a proliferation marker in a wide variety of solid tumours, and to assess its potential value in predicting clinical outcome. Methods and results: Using immunocytochemistry on paraffin‐embedded tissue sections, the CAF‐1 labelling index was compared with known proliferation markers Ki‐67 and minichromosome maintenance (MCM), and its association with clinicopathological data and patients’ outcome analysed. CAF‐1 expression showed a strong positive correlation with Ki‐67, used routinely to detect proliferating cells, while it generally displayed weaker correlations with MCM markers, known to label cells with replicative potential. CAF‐1 expression was associated significantly with histological grade in breast, cervical, endometrial and renal cell carcinomas, and with disease stage in endometrial and renal carcinomas. Furthermore, high expression of CAF‐1 was an independent predictor of adverse clinical outcome in renal, endometrial and cervical carcinomas. Conclusions: CAF‐1 is a proliferation marker in various malignant tumours with prognostic value in renal, endometrial and cervical carcinomas, which supports the value of CAF‐1 as a clinical marker of cancer progression.